448 related articles for article (PubMed ID: 29109163)
1. Evaluation of Oritavancin Dosing Strategies against Vancomycin-Resistant Enterococcus faecium Isolates with or without Reduced Susceptibility to Daptomycin in an
Belley A; Arhin FF; Moeck G
Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29109163
[TBL] [Abstract][Full Text] [Related]
2. Comparative Pharmacodynamics of Single-Dose Oritavancin and Daily High-Dose Daptomycin Regimens against Vancomycin-Resistant Enterococcus faecium Isolates in an
Belley A; Lalonde-Séguin D; Arhin FF; Moeck G
Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784674
[TBL] [Abstract][Full Text] [Related]
3. Utilizing genomic analyses to investigate the first outbreak of vanA vancomycin-resistant Enterococcus in Australia with emergence of daptomycin non-susceptibility.
Douglas AP; Marshall C; Baines SL; Ritchie D; Szer J; Madigan V; Chan HT; Ballard SA; Howden BP; Buising K; Slavin MA
J Med Microbiol; 2019 Mar; 68(3):303-308. PubMed ID: 30663951
[TBL] [Abstract][Full Text] [Related]
4. Antimicrobial susceptibility of bacteremic vancomycin-resistant Enterococcus faecium to eravacycline, omadacycline, lipoglycopeptides, and other comparator antibiotics: Results from the 2019-2020 Nationwide Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART).
Tsai HY; Lee YL; Liu PY; Lu MC; Shao PL; Lu PL; Cheng SH; Ko WC; Lin CY; Wu TS; Yen MY; Wang LS; Liu CP; Lee WS; Shi ZY; Chen YS; Wang FD; Tseng SH; Chen YH; Sheng WH; Lee CM; Chen YH; Liao CH; Hsueh PR
Int J Antimicrob Agents; 2021 Jul; 58(1):106353. PubMed ID: 33961991
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of oritavancin alone or in combination against vancomycin-susceptible and -resistant enterococci.
Wu T; Meyer K; Harrington AT; Danziger LH; Wenzler E
J Antimicrob Chemother; 2019 May; 74(5):1300-1305. PubMed ID: 30753495
[TBL] [Abstract][Full Text] [Related]
6. In vitro stepwise selection of reduced susceptibility to lipoglycopeptides in enterococci.
Arhin FF; Seguin DL; Belley A; Moeck G
Diagn Microbiol Infect Dis; 2017 Oct; 89(2):168-171. PubMed ID: 28733126
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model.
Hall Snyder A; Werth BJ; Barber KE; Sakoulas G; Rybak MJ
J Antimicrob Chemother; 2014 Aug; 69(8):2148-54. PubMed ID: 24777900
[TBL] [Abstract][Full Text] [Related]
8. Oritavancin Combinations with β-Lactams against Multidrug-Resistant Staphylococcus aureus and Vancomycin-Resistant Enterococci.
Smith JR; Yim J; Raut A; Rybak MJ
Antimicrob Agents Chemother; 2016 Apr; 60(4):2352-8. PubMed ID: 26833159
[TBL] [Abstract][Full Text] [Related]
9. Vancomycin-resistant Enterococcus faecium in Algeria: phenotypic and genotypic characterization of clinical isolates.
Benamrouche N; Guettou B; Henniche FZ; Assaous F; Laouar H; Ziane H; Djennane F; Tiouit D; Bentchouala C; Yamouni F; Rahal K; Tali Maamar H
J Infect Dev Ctries; 2021 Jan; 15(1):95-101. PubMed ID: 33571151
[TBL] [Abstract][Full Text] [Related]
10. Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
McKay GA; Beaulieu S; Arhin FF; Belley A; Sarmiento I; Parr T; Moeck G
J Antimicrob Chemother; 2009 Jun; 63(6):1191-9. PubMed ID: 19369269
[TBL] [Abstract][Full Text] [Related]
11. 1,2,4-Oxadiazole antimicrobials act synergistically with daptomycin and display rapid kill kinetics against MDR Enterococcus faecium.
Carter GP; Harjani JR; Li L; Pitcher NP; Nong Y; Riley TV; Williamson DA; Stinear TP; Baell JB; Howden BP
J Antimicrob Chemother; 2018 Jun; 73(6):1562-1569. PubMed ID: 29518208
[TBL] [Abstract][Full Text] [Related]
12. Institution-wide and Within-Patient Evolution of Daptomycin Susceptibility in Vancomycin-Resistant Enterococcus faecium Bloodstream Infections.
Woods RJ; Patel TS; Nagel JL; Newton DW; Read AF
Infect Control Hosp Epidemiol; 2018 Feb; 39(2):226-228. PubMed ID: 29331166
[TBL] [Abstract][Full Text] [Related]
13. Daptomycin susceptibility testing and therapeutic use in enterococcal bloodstream infection (EBSI) in a setting with high rates of vancomycin-resistant Enterococcus faecium (VREfm).
Kelly J; Tysall L; Dewar S
J Antimicrob Chemother; 2022 Apr; 77(5):1432-1435. PubMed ID: 35165738
[TBL] [Abstract][Full Text] [Related]
14. Rapid in vivo development of resistance to daptomycin in vancomycin-resistant Enterococcus faecium due to genomic alterations.
Mollerup S; Elmeskov C; Pinholt M; Sejersen TS; Pedersen MS; Worning P; Frees D; Westh H
FEMS Microbiol Lett; 2022 Aug; 369(1):. PubMed ID: 35922088
[TBL] [Abstract][Full Text] [Related]
15. Clinically Applicable System for Rapidly Predicting Enterococcus faecium Susceptibility to Vancomycin.
Wang HY; Chung CR; Chen CJ; Lu KP; Tseng YJ; Chang TH; Wu MH; Huang WT; Lin TW; Liu TP; Lee TY; Horng JT; Lu JJ
Microbiol Spectr; 2021 Dec; 9(3):e0091321. PubMed ID: 34756065
[TBL] [Abstract][Full Text] [Related]
16. Impact of Daptomycin Dose Exposure Alone or in Combination with β-Lactams or Rifampin against Vancomycin-Resistant Enterococci in an
Jahanbakhsh S; Singh NB; Yim J; Kebriaei R; Smith JR; Lev K; Tran TT; Rose WE; Arias CA; Rybak MJ
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094136
[No Abstract] [Full Text] [Related]
17. Daptomycin against multiple drug-resistant staphylococcus and enterococcus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations.
Cha R; Rybak MJ
Diagn Microbiol Infect Dis; 2003 Nov; 47(3):539-46. PubMed ID: 14596973
[TBL] [Abstract][Full Text] [Related]
18. Establishment and Persistence of Glycopeptide-Resistant
Rodríguez-Lucas C; Fernández J; Raya C; Bahamonde A; Quiroga A; Muñoz R; Rodicio MR
Microb Drug Resist; 2022 Feb; 28(2):217-221. PubMed ID: 34705570
[TBL] [Abstract][Full Text] [Related]
19. Pharmacodynamics of a simulated single 1,200-milligram dose of oritavancin in an in vitro pharmacokinetic/pharmacodynamic model of methicillin-resistant staphylococcus aureus infection.
Belley A; Arhin FF; Sarmiento I; Deng H; Rose W; Moeck G
Antimicrob Agents Chemother; 2013 Jan; 57(1):205-11. PubMed ID: 23089749
[TBL] [Abstract][Full Text] [Related]
20. Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections.
Arias CA; Mendes RE; Stilwell MG; Jones RN; Murray BE
Clin Infect Dis; 2012 Apr; 54 Suppl 3(Suppl 3):S233-8. PubMed ID: 22431854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
